Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MHLW Minister Says Pharmaceuticals Companies Should Apologize For Hepatitis C Victims

This article was originally published in PharmAsia News

Executive Summary

The compensation package for hepatitis C patients who used contaminated blood products takes effect on January 16. At a press briefing announcing the news, Japan's Minister of Health, Labor and Welfare Yoichi Masuzoe pointed out that the primary responsibility lies with drug makers, and they should reflect on their roles in the contaminations and apologize. "I expect them to take appropriate responsibilities since the drug makers are not included in the basic agreement package," Masuzoe said. He also urged the pharmaceutical companies to work with the government to resolve the problem.Regarding the compensation cost share by the government and drug companies, Masuzoe said drug companies should contribute two-thirds of the cost, and the government should cover one-third, but concrete numbers are still in negotiations. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066635

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel